Curated News
By: NewsRamp Editorial Staff
July 13, 2026

VERAXA Biotech Appoints Carl von Halem as Interim CFO

Discuss on LinkedIn Discuss on X, formerly Twitter Discuss on Substack Discuss on Telegram participate in discussion on bluesky Participate in discussion on Mastodon View History of this news story on GitHub
Original Source

TLDR

  • VERAXA Biotech appoints Carl von Halem as interim CFO, leveraging his expertise for strategic growth and competitive edge.
  • Carl von Halem, interim CFO at VERAXA, brings corporate finance and life sciences experience to lead the finance function during transition.
  • VERAXA's leadership transition aims to advance antibody-based therapeutics, potentially improving treatments for patients worldwide.
  • VERAXA's BiTAC technology, developed from EMBL breakthroughs, targets cancer with innovative bispecific antibody formats.

Impact - Why it Matters

This CFO transition matters because VERAXA is in a critical growth phase, advancing its pipeline of next-generation antibody-based therapeutics. The appointment of an experienced interim CFO with deep knowledge of the company ensures financial stability during the search for a permanent leader, which is key to maintaining investor confidence and supporting expansion into clinical development.

Summary

VERAXA Biotech (NASDAQ: VRXA) has appointed Carl von Halem as interim chief financial officer, succeeding Torsten Bürgermeister, as the company navigates a key leadership transition. Von Halem, who currently serves as CFO of Xlife Sciences, brings extensive experience in corporate finance, life sciences, and technology-driven businesses. Importantly, he played a pivotal role in VERAXA’s public listing, giving him deep familiarity with the company’s operations and strategic direction. The company stated it is in the final stages of discussions with a permanent CFO candidate who is expected to support its next phase of expansion and operational growth, with an update to be provided in due course.

VERAXA is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other innovative formats. Powered by transformative technologies and guided by rigorous quality-by-design principles, the company is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development. BiTAC(R) is a registered trademark of VERAXA Biotech GmbH. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research.

For investors seeking the latest news and updates on VRXA, the company’s newsroom is available at http://nnw.fm/VRXA. To view the full press release, visit https://nnw.fm/BjjY6. This transition comes at a critical time as VERAXA positions itself for accelerated growth in the competitive biotech landscape.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, VERAXA Biotech Appoints Carl von Halem as Interim CFO

blockchain registration record for this content.